FIDAS-3 is a stilbene derivative and is a potent Wnt inhibitor with an IC50 of 4.9 μM for methionine S-adenosyltransferase 2A (MAT2A). FIDAS-3 effectively competes against S-adenosylmethionine (SAM) for MAT2A binding. FIDAS-3 has anticancer activities.
FIDAS-3 (3 μM; 7 days; LS174T cells) treatment significantly inhibits the proliferation of LS174T cells.
FIDAS-3 (3-10 μM) treatment inhibits the expression of c-Myc and cyclinD1 in LS174T CRC cells. And FIDAS-3 induces the expression of cell cycle inhibitor, p21.
FIDAS-3 (10 μM; 36 h) treatment reduces the levels of both S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) in LS174T cells.
Cell Viability Assay
Cell Line:
LS174T colorectal cancer (CRC) cells
Concentration:
3 μM
Incubation Time:
7 days
Result:
Significantly inhibited the proliferation of LS174T cells.
体内研究
FIDAS-3 (20 mg/kg; intraperitoneal injection; daily; for one months; C57BL/6J athymic nude mice) treatment significantly inhibits the growth of xenograft tumors.
Animal Model:
C57BL/6J athymic nude mice (6-8 week) injected with LS174 cells
Dosage:
20 mg/kg
Administration:
Intraperitoneal injection; daily; for one months
Result:
Significantly inhibited the growth of xenograft tumors.
分子式
C16H15F2N
分子量
259.29
CAS号
1266684-01-8
运输条件
Room temperature in continental US; may vary elsewhere.